No Data
No Data
Treace to Report First Quarter 2025 Financial Results on May 8, 2025
BTIG Maintains Treace Medical Concepts(TMCI.US) With Buy Rating, Cuts Target Price to $14
BTIG Sticks to Its Buy Rating for Treace Medical Concepts (TMCI)
Truist Financial Maintains Treace Medical Concepts(TMCI.US) With Hold Rating, Cuts Target Price to $8
Treace Medical Concepts Analyst Ratings
Truist Cuts Price Target on Treace Medical Concepts to $8 From $9.50, Keeps Hold Rating